Chong Kun Dang Pharmaceutical Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Young-Joo Kim
Chief executive officer
n/a
Total compensation
CEO salary percentage | n/a |
CEO tenure | 3.8yrs |
CEO ownership | n/a |
Management average tenure | no data |
Board average tenure | 4.3yrs |
Recent management updates
Recent updates
Is Chong Kun Dang Pharmaceutical (KRX:185750) Using Too Much Debt?
Oct 24Investors Aren't Buying Chong Kun Dang Pharmaceutical Corp.'s (KRX:185750) Earnings
Sep 27Does Chong Kun Dang Pharmaceutical (KRX:185750) Deserve A Spot On Your Watchlist?
Sep 08Are Investors Undervaluing Chong Kun Dang Pharmaceutical Corp. (KRX:185750) By 41%?
Jul 30Investors Don't See Light At End Of Chong Kun Dang Pharmaceutical Corp.'s (KRX:185750) Tunnel
Jun 12Chong Kun Dang Pharmaceutical (KRX:185750) Seems To Use Debt Rather Sparingly
May 27A Look At The Fair Value Of Chong Kun Dang Pharmaceutical Corp. (KRX:185750)
Apr 09Does Chong Kun Dang Pharmaceutical (KRX:185750) Have A Healthy Balance Sheet?
Apr 19Here's Why I Think Chong Kun Dang Pharmaceutical (KRX:185750) Is An Interesting Stock
Apr 05Declining Stock and Solid Fundamentals: Is The Market Wrong About Chong Kun Dang Pharmaceutical Corp. (KRX:185750)?
Mar 09Estimating The Fair Value Of Chong Kun Dang Pharmaceutical Corp. (KRX:185750)
Feb 24The Chong Kun Dang Pharmaceutical (KRX:185750) Share Price Is Up 112% And Shareholders Are Boasting About It
Feb 11Is Chong Kun Dang Pharmaceutical Corp. (KRX:185750) An Attractive Dividend Stock?
Jan 27Does Chong Kun Dang Pharmaceutical (KRX:185750) Have A Healthy Balance Sheet?
Jan 12With EPS Growth And More, Chong Kun Dang Pharmaceutical (KRX:185750) Is Interesting
Dec 28What Kind Of Shareholders Hold The Majority In Chong Kun Dang Pharmaceutical Corp.'s (KRX:185750) Shares?
Dec 09Could The Market Be Wrong About Chong Kun Dang Pharmaceutical Corp. (KRX:185750) Given Its Attractive Financial Prospects?
Nov 24CEO
Young-Joo Kim
3.8yrs
Tenure
Mr. Young-Joo Kim serves as the President, Chief Executive Officer and Director of Chong Kun Dang Pharmaceutical Corp. and serves as its Chairman since March 26, 2021.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 3.8yrs | no data | no data | |
Full-Time Auditor | 4.8yrs | no data | no data | |
Independent Outside Director | 5.8yrs | no data | no data | |
Director | less than a year | no data | no data |
4.3yrs
Average Tenure
Experienced Board: A185750's board of directors are considered experienced (4.3 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/28 09:30 |
End of Day Share Price | 2024/12/27 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Chong Kun Dang Pharmaceutical Corp. is covered by 19 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Hyerin Lee | DAOL Investment & Securities Co., Ltd. |
Jisoo Lee | DAOL Investment & Securities Co., Ltd. |
null null | DBS Bank Ltd |